Loading stock data…
SCL
$52.64+1.21 (+2.35%)
Market OpenUpdated 3:52 PM EDT
Stepan Company, together with its subsidiaries, produces and sells specialty and intermediate chemicals to other manufacturers for use in various end products in the United States, France, Poland, the United Kingdom, Brazil, Mexico, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Stepan Company in the Basic Materials sector is trading at $52.64 with a market capitalization of $1.2B. Wall Street consensus targets $75.00 (1 analysts), implying a +42.5% move over the next 12 months. The stock is currently 23% below its 52-week high of $68.00, remaining 7.1% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +42.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$52.64
Potential Downside
0%
Whystock Fair Value$52.64
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Stepan Company, together with its subsidiaries, produces and sells specialty and intermediate chemicals to other manufacturers for use in various end products in the United States, France, Poland, the United Kingdom, Brazil, Mexico, and international...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.17B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.95
Div Yield
Strong income play. Yield provides a meaningful total return floor.
2.26%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1.19%
Volume
Today's trading volume
72,649
Recent News
A Look At Stepan (SCL) Valuation After Recent Share Price Weakness
Stepan (SCL) is back on investors’ radar after recent trading pressure, with the stock down 4% over the past month and 26% over the past 3 months, which has sharpened the focus on fundamentals. See our latest analysis for Stepan. Recent trading has been weak, with the stock down 26% on a 90 day share price return basis and the 1 year total shareholder return slipping 9%, pointing to fading momentum despite a positive year to date share price return of 4%. If Stepan’s recent pullback has you...
Stepan Co (SCL) Q1 2026 Earnings Call Highlights: Record Safety Performance Amidst Challenges
Stepan Co (SCL) reports strong safety achievements and growth in specialty products, despite facing restructuring charges and market pressures.
Stepan Q1 Earnings Call Highlights
Stepan (NYSE:SCL) reported a first-quarter 2026 net loss as restructuring charges tied to its asset footprint changes overshadowed modest organic sales growth and mixed segment performance. Management also emphasized progress on its multi-year cost and asset optimization initiative, Project Catalyst
Stepan Company Q1 2026 Earnings Call Summary
Moby summary of Stepan Company's Q1 2026 earnings call
Stepan (SCL) Q1 2025 Earnings Call Transcript
Luis Rojo: Thank you, Sam. Surfactant and Specialty Products delivered double-digit adjusted EBITDA growth while Polymers adjusted EBITDA decreased slightly year-over-year. Volume grew 4% and the growth was broad-based with Surfactants up 3%, Polymers up 7% and our MCT product line up 4%.